More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.07B
EPS
2.29
P/E ratio
7.2
Price to sales
7.11
Dividend yield
--
Beta
1.40574
Previous close
$15.73
Today's open
$15.73
Day's range
$15.30 - $15.81
52 week range
$13.52 - $19.25
show more
CEO
Kevin Tang
Employees
128
Headquarters
Edmonton, AB
Exchange
NASDAQ Global Market
Shares outstanding
133998660
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. Net Product Sales: For th.
Business Wire • Oct 30, 2026

Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.23 per share a year ago.
Zacks Investment Research • Oct 30, 2026

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 27, 2026

Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Oct 26, 2026

Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research • Oct 23, 2026

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Zacks Investment Research • Aug 20, 2026

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
Benzinga • Aug 20, 2026

Aurinia Settles Patent Litigation with Teva
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
Business Wire • Aug 19, 2026

Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.
Seeking Alpha • Aug 12, 2026

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.
Business Wire • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Aurinia Pharmaceuticals Inc commission-free¹. Build wealth for the long term using automated trading and transfers.